Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Tumor antigens.

J L Urban¹, H Schreiber

¹Department of Pathology, University of Chicago, Illinois 60637.

Annual Review of Immunology

|January 1, 1992

Summary

Human cancers possess unique mutant proteins recognized as tumor antigens. These antigens offer potential for cancer diagnosis, immunotherapy, and vaccines, targeting multiple sites for effective immune attack.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Patient profiling in relapsing multiple sclerosis: insights from a real-world observational study into the unmet medical needs of patients on disease-modifying therapy.

Journal of neurology·2026

Same author

The impact of fetal sex on pregnancy and neonatal outcomes in twin gestation.

Archives of gynecology and obstetrics·2024

Same author

[Neuropsychological and MRI diagnostics in secondary progressive multiple sclerosis].

Der Nervenarzt·2021

Same author

The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): results from the German validation study.

Journal of neurology·2018

Same author

Baseline predictors of persistence to first disease-modifying treatment in multiple sclerosis.

Acta neurologica Scandinavica·2016

Same author

Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.

Acta neurologica Scandinavica·2014

Area of Science:

Oncology
Immunology
Molecular Biology

Background:

Human cancers, both common and rare, contain tumor-specific mutant proteins.
These proteins arise from mutations in oncogenes and suppressor genes, including point mutations, translocations, deletions, and viral insertions, often forming fusion proteins.

Purpose of the Study:

To review the concept of tumor-specific mutant proteins as antigens in human cancers.
To explore their potential roles in cancer diagnosis, immunotherapy, and vaccine development.
To discuss the immunological relevance and therapeutic targeting of these mutant proteins.

Main Methods:

Review of existing scientific literature and evidence from mouse and human studies.
Analysis of the molecular basis of tumor-specific antigen generation.
Evaluation of T cell recognition and immune response to mutant proteins.

Main Results:

Tumor-specific mutant proteins are recognized as antigens by the immune system.
These antigens can be targeted for diagnosis and immunotherapy, and potentially for preventive vaccines.
Cytolytic and helper T cells show high selectivity for intracellular mutant proteins, aiding in mutation identification.
Malignant cells often express multiple antigenic targets, enabling multi-pronged immune attacks and reducing tumor escape.

Conclusions:

Tumor-specific mutant proteins are crucial targets for cancer immunotherapy and diagnosis.
The multiplicity of antigenic targets on cancer cells enhances the potential for successful immune-mediated tumor rejection.
Future research should focus on engineering immunogenic tumor mutant peptides for enhanced therapeutic efficacy.

Related Experiment Videos